PGENPrecigen, IncNot started yet
Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children
Recurrent Respiratory Papillomatosis (RRP) · Juvenile-onset Recurrent Respiratory Papillomatosis · Papillomavirus Infections
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
5 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 15 (planned)
- Started
- Dec 31, 2026
- Main results expected
- Jan 2029
- Fully finished
- Jan 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete response rate
Measured over: 12 months following last administration of study drug
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07901738 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC